Pooled progression free and overall survival based on the 24 month cut-off. PFS (A) and OS (B) according to the relapse subgroup (<24 and ≥24 months) in the pooled CASTOR/POLLUX population. Kaplan-Meier plots of PFS and OS in patients with 1 prior line of therapy who progressed or relapsed early or late after initiation of first line of therapy. The early-relapse subgroup included intent-to-treat (ITT) patients with 1 prior line of therapy who progressed or relapsed <24 months after initiating their first line of therapy; the late-relapse subgroup included ITT patients with 1 prior line of therapy who progressed or relapsed ≥24 months after initiating their first line of therapy. DARA, daratumumab.